吡柔比星为主的联合化疗方案治疗晚期乳腺癌临床疗效分析

目的观察吡柔比星为主的联合化疗方案治疗晚期乳腺癌近期疗效、毒副反应。方法40例晚期乳腺癌患者,接受以吡柔比星为主的联合化疗方案治疗,按WHO疗效及毒副反应评价标准,完成两个周期以上治疗的患者进行临床疗效及不良反应评估。结果40例化疗患者总有效率(RR)达57.5%,稳定(NC)占25%,进展(PD)占17.5%。中位缓解期为6(4～1 3)个月,中位生存期11(6～18)个,一年生存率为58.9%。主要毒副反应为骨髓抑制,非血液毒性反应较轻,主要为Ⅰ-Ⅱ度胃肠道反应。结论吡柔比星为主的联合化疗方案治疗晚期乳腺癌患者临床疗效明显,不良反应轻,能提高生存率。

Objective To observe the efficacy and toxicity of Epirubicin Hydrochloride For Injection plus in the Treatment of advance Breast cancer. Methods Of 40 case advance Breast cancer, Treated with Epirubicin Hydrochloride For Injection plus. The pationt＇ s clinical efficacy and adverse effect were evaluated after two cycles of chemotheropy according to WHO standard. Results The resporise rate（CR＋PR） was 57.5%. The medicin remission was 6 （4- 1 3 ） months and median survial time was 11（6-18）months And one year survival rate was 58.9%. Bone marron suppression was the important adverse effect. The gastronintestinal toxicity grad was Ⅰ-Ⅱ. Conclusion The Epirubicin Hydrochloride For Injection plus in the Treatment of advance Breast cancer has good efficary, light adverse effect and increased survival rate.